EVMN Earnings & Financial Statements
Evommune, Inc.
$5.77
-$0.11(-1.87%)
16
Overall
--
Value
9
Tech
23
Quality
Market Cap
$213.40M
Volume
574.84K
52W Range
$6.02 - $33.20
Target Price
$24.00
EVMN earnings and financial statements: Evommune, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
EVMN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $13.00M | $7.00M | $5.00M |
| Operating income | -$81.07M | -$70.01M | -$37.85M |
| EBITDA | -$67.48M | -$65.48M | -$33.05M |
| Net income | -$68.87M | -$66.81M | -$34.05M |
| EPS (diluted) | $-11.22 | $-45.29 | $-27.17 |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total assets | $224.95M | $76.06M | $82.25M |
| Total liabilities | $19.38M | $28.52M | $10.59M |
| Shareholders’ equity | $205.57M | $47.54M | $71.66M |
| Cash and equivalents | $44.06M | $16.25M | $29.02M |
| Long-term debt | $1.47M | $535.0K | $487.0K |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating cash flow | -$76.44M | -$58.20M | -$29.97M |
| Capital expenditure | -$235.0K | - | - |
| Free cash flow | -$76.68M | -$58.28M | -$30.09M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EVMN | $5.77 | -1.9% | 574.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |